Onaran Y, Tezelman S, Gürel N, Terzioğlu T, Oğuz H, Tanakol R, Kapran Y
Department of General Surgery, Istanbul Medical Faculty, Turkey.
Acta Chir Belg. 1999 Feb;99(1):30-5.
DNA content of tumour was found to correlate with various prognostic factors and survival, especially in well differentiated thyroid carcinoma. The aim of this investigation was to evaluate the correlation between the DNA ploidy and the prognosis as well as the survival in thyroid carcinoma in our country, being an endemic iodine deficiency region. DNA flowcytometry was performed on paraffin embedded archival tissue blocs of 74 patients with thyroid carcinoma (70 well differentiated, 3 anaplastic and Hurthle cell carcinoma) and 12 patients with multinodular goitre. DNA ploidy was defined as diploidy or aneuploidy. Aneuploidy was detected in 5 (6.8%) patients with thyroid carcinoma (3 anaplastic, 1 papillary and 1 Hurthle cell carcinoma). Aneuploidy was significantly more frequent in patients with anaplastic carcinoma (n: 3/3, 100%) compared to well differentiated thyroid carcinoma (n: 1/70, 1.4%) (p < 0.0001). Aneuploid DNA content significantly correlated with advanced age (p < 0.01), large tumour size (p < 0.001), and low survival (p < 0.01). Mean survival period of patients with anaplastic carcinoma in whom aneuploidy was frequently encountered, was shorter compared to patients with diploid well differentiated tumours (p < 0.01). In conclusion, although anaplastic and follicular carcinoma are more frequently diagnosed in endemic areas, the rate on aneuploidy was found to be lower in thyroid carcinoma in our country compared to data reported to nonendemic areas. As the prognostic predictive value of DNA ploidy is reliable in well differentiated thyroid carcinoma, DNA measurement of FNA biopsy may influence the extent of surgery. Thyroid carcinoma, other than well differentiated types, require radical operations independent of the DNA content. However, adjunctive treatment methods may be used earlier postoperatively according to quantitative DNA measurement.
研究发现肿瘤的DNA含量与多种预后因素及生存率相关,尤其是在高分化甲状腺癌中。本研究的目的是评估在我国这个碘缺乏流行地区,甲状腺癌的DNA倍体与预后及生存率之间的相关性。对74例甲状腺癌患者(70例高分化、3例间变性和许特莱细胞癌)以及12例多结节性甲状腺肿患者的石蜡包埋存档组织块进行了DNA流式细胞术检测。DNA倍体被定义为二倍体或非整倍体。在5例(6.8%)甲状腺癌患者中检测到非整倍体(3例间变性、1例乳头状和1例许特莱细胞癌)。与高分化甲状腺癌(n: 1/70, 1.4%)相比,间变性癌患者中出现非整倍体的频率显著更高(n: 3/3, 100%)(p < 0.0001)。非整倍体DNA含量与高龄(p < 0.01)、肿瘤体积大(p < 0.001)及低生存率(p < 0.01)显著相关。与二倍体高分化肿瘤患者相比,经常出现非整倍体的间变性癌患者的平均生存期更短(p < 0.01)。总之,尽管在流行地区间变性癌和滤泡癌的诊断更为频繁,但我国甲状腺癌中非整倍体的发生率与非流行地区报道的数据相比更低。由于DNA倍体的预后预测价值在高分化甲状腺癌中是可靠的,细针穿刺活检的DNA测量可能会影响手术范围。除高分化类型外的甲状腺癌,无论DNA含量如何,都需要进行根治性手术。然而,根据DNA定量测量,术后可能更早地使用辅助治疗方法。